| Document |
Document Title |
|
WO/2023/277620A1 |
The present invention relates to use of a combination comprising: a peptide or a conjugate thereof, having activity on all of glucagon, GLP-1 and GIP receptor; and a SGLT-2 inhibitor.
|
|
WO/2023/272794A1 |
A combined pharmaceutical composition for preventing cardiovascular diseases complicated by hypertension, comprising a homocysteine reducing drug and a platelet reducing drug. The homocysteine reducing drug is folic acid, and the platele...
|
|
WO/2023/274095A1 |
An application of a kaurane compound in the preparation of a drug for treating inflammatory bowel disease. The kaurane compound can mitigate the inflammatory reaction of dextran sodium sulfate (DSS)-induced inflammatory bowel disease mod...
|
|
WO/2023/278497A1 |
The invention disclosed herein relates to novel methods, and compositions, for preventing, inhibiting, reducing, and/or shortening the duration of symptoms associated with the consumption of alcohol and/or hangover symptoms associated wi...
|
|
WO/2023/275622A2 |
The invention generally relates to methods and systems for controlling electrolyte excretion, e.g., sodium, potassium, chloride and bicarbonate, which is useful to remove body fluid during sweating.
|
|
WO/2023/275249A1 |
The present invention relates to anethole trithione (ATT) for use for preventing, treating, and/or lessening the severity or progression of, a vasculitis in a subject in need thereof, in particular of Kawasaki and Kawasaki-like disease.
|
|
WO/2023/278987A1 |
Provided herein are methods for the add-on treatment of schizophrenia using a vesicular monoamine transporter isoform 2 (VMAT2) inhibitor. In certain embodiments, the VMAT2 inhibitor is valbenazine or a pharmaceutically acceptable salt t...
|
|
WO/2023/276942A1 |
Disclosed is a pharmaceutical agent that inhibits expression of VEGFA in fibroblasts. This pharmaceutical agent can inhibit increase in expression of VEGFA in fibroblasts caused by infrared rays, heat, etc.
|
|
WO/2023/274418A1 |
A novel proteolysis-targeting chimeric compound, and an application thereof in the preparation of a drug for treating related diseases. A compound represented by formula (I) and a pharmaceutically-acceptable salt thereof are specifically...
|
|
WO/2023/277610A1 |
The present invention relates to: a pharmaceutical composition which, by loading a nucleic acid-based drug in cell-derived natural or artificial nanovesicles, is capable of introducing the nucleic acid-based drug into cells; and a method...
|
|
WO/2023/276866A1 |
The present invention pertains to a therapeutic composition for Barrett's esophagus and addresses the problem of providing a therapeutic composition for restoring Barrett's esophagus to normal esophagus and a method for treating Barrett'...
|
|
WO/2023/272607A1 |
A diagnosis and treatment integrated apoptotic body and a preparation method therefor. The preparation method comprises: culturing cells in a culture medium containing an antitumor drug and a nano contrast agent to obtain a culture mediu...
|
|
WO/2022/271861A1 |
The invention generally relates to pharmaceuticals and therapeutic methods. More particularly, the invention provides small molecule EGFR inhibitors (e.g., EGFR tyrosine kinase inhibitor compounds) and pharmaceutical compositions thereof...
|
|
WO/2022/269266A1 |
A composition comprising an agonist of a 5-hydroxytryptamine (5-HT) receptor subtype 2A, 2B or 2C (5-HT2A, 5-HT2B or 5-HT2C), for the use in the treatment of a cognitive or neurological disorder in a patient, said patient having been pre...
|
|
WO/2022/269265A1 |
A composition comprising an agonist of a 5-hydroxytryptamine (5-HT) receptor subtype 3, for the use in the treatment of a cognitive or neurological disorder in a patient, said patient having been pre-treated with naltrexone, or a metabol...
|
|
WO/2022/270071A1 |
The present invention provides: an agent for preventing liver fibrosis, which comprises at least one nucleic acid selected from the group consisting of a nucleic acid that comprises a nucleotide sequence comprising a seed sequence for mi...
|
|
WO/2022/269267A1 |
A pharmaceutical composition comprising naltrexone or a metabolite thereof or an analogue selected from the group consisting of methylnaltrexone, nalmefene and nalorphine, for use in the treatment of an autoimmune disease within a subjec...
|
|
WO/2022/271604A1 |
Provided herein are methods of treating a patient infected with a coronavirus and having a baseline level of CRP below 150 mg/L, comprising administering to the patient a compound of formula 1: (1) or a pharmaceutically-acceptable salt t...
|
|
WO/2022/272124A1 |
Disclosed are hemoglobin-based oxygen carriers (HBOCs) that comprise a polymer-functionalized polymerized hemoglobin, such as a polyalkylene oxide (PAO)-functionalized polymerized hemoglobin, as well as compositions comprising these HBOC...
|
|
WO/2022/269439A1 |
A composition for use in treating a subject with diabetes or pre-diabetes includes an effective amount of a phenyl propionic acid of the Formula (I), an isomer, or a pharmaceutically acceptable salt thereof, and the composition lowers on...
|
|
WO/2022/271658A1 |
The present embodiments provide compounds of Formula (I), compositions of the compounds, and methods for treating diseases such as cancer.
|
|
WO/2022/270972A1 |
Provided are a use, a pharmaceutical composition, and a method for efpeglenatide for reducing a risk of developing a cardiovascular disease or renal dysfunction. The efpeglenatide may be used for cardiovascular or renal protection of pat...
|
|
WO/2022/272106A1 |
The present disclosure relates generally to Cyclin-dependent kinase 2 (CDK2) inhibiting chemical compounds and uses thereof in the inhibition of the activity of CDK2. The disclosure also provides pharmaceutically acceptable compositions ...
|
|
WO/2022/268738A1 |
The present invention relates to a combination comprising at least one monoamine reuptake inhibitor and at least one potassium-chloride cotransporter type 2 expression-enhancing compounds (KEEC). The present invention also relates to a p...
|
|
WO/2022/270523A1 |
This medicament characterized by containing an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein together or separately in combination with a pyrimidine drug, a platinum formulation, and an angioge...
|
|
WO/2022/269525A1 |
The present invention relates to a pharmaceutical combination comprising a KRAS G12C inhibitor and one or more therapeutic agents which is selected from an agent targeting the MARK pathway or an agent targeting parallel pathways; and pha...
|
|
WO/2022/271547A1 |
The present invention relates to combinations useful in the treatment of cancer. In particular, the present invention relates to a combination comprising a poly (ADP-ribose) polymerase inhibitor (PARP inhibitor) and a lipophilic statin, ...
|
|
WO/2022/268969A1 |
The present invention relates to a cephalosporin for use in a method of preventing and/or treating colon cancer, wherein the cephalosporin comprises a nitrogen, preferably positively charged nitrogen, and a first carboxyl group, preferab...
|
|
WO/2022/269064A1 |
The present invention provides a pharmaceutical combination of nicotinamide riboside with methyl donor(s) for use in a method for treatment of Parkinson's disease (PD) in a human subject; a pharmaceutical composition for use in such meth...
|
|
WO/2022/269264A1 |
A single unit oral dose pharmaceutical composition for use as a medicament for separate, sequential or simultaneous administration with an agonist of a 5- hydroxytryptamine (5-HT) receptor; wherein the single unit oral dose pharmaceutica...
|
|
WO/2022/270760A1 |
The present invention relates to a pharmaceutical composition, quasi-drug, and food composition for preventing, ameliorating or treating steatohepatitis, comprising a curcumin derivative and a TGF-β receptor inhibitor as active ingredie...
|
|
WO/2022/268056A1 |
Tissue-targeting exosomes and an application thereof. The tissue-targeting exosomes comprise exosomes which target bladder tissue, colorectal tissue, lung tissue, kidney tissue, stomach tissue, liver tissue, heart tissue, pancreatic tiss...
|
|
WO/2022/269066A1 |
The present invention provides nicotinamide riboside for use in a method for treatment of Parkinson's disease (PD) in a human subject; a pharmaceutical composition for use in such method, the composition comprising nicotinamide riboside;...
|
|
WO/2022/270621A1 |
Lysophosphatidic acid (LPA) has been found to function as a mediator that promotes invasiveness in osteosarcoma. In addition, it has been discovered that LPAR1, which is a receptor for LPA, is highly expressed in osteosarcoma and glioma,...
|
|
WO/2022/270612A1 |
The present disclosure provides an anti-CTLA-4 antibody and methods for producing and using same. The present disclosure also provides: a nucleic acid encoding said anti-CTLA-4 antibody; and host cells including said nucleic acid. The pr...
|
|
WO/2022/262624A1 |
The present invention belongs to the field of biomedicine, and relates to a pharmaceutical use of β2-microglobulin or an inhibitor thereof. In particular, the present invention relates to a use of β2-microglobulin or an inhibitor there...
|
|
WO/2022/266285A1 |
Therapeutic methods and pharmaceutical compositions for treating symptoms associated with myeloproliferative neoplasms in a human subject are described. In certain embodiments, the disclosure includes therapeutic methods of treating symp...
|
|
WO/2022/265509A1 |
The invention relates to a pharmaceutical composition, as well as a dosage comprising said pharmaceutical composition, for use in the treatment of a mitochondrial activity related disease or disorder and/or of an adiponectin production r...
|
|
WO/2022/265912A1 |
Antibodies and antibody-drug conjugates that selectively bind to a membrane-associated extracellular portion of a cleaved amphiregulin precursor protein; methods of using the antibodies and antibody-drug conjugates to detect and inhibit ...
|
|
WO/2022/262516A1 |
A linker, comprising an Lb structure fragment, the Lb structure being selected from the following formula, wherein subscript q is selected from any integer from 1 to 20, preferably from 3 to 10, and most preferably from 5 to 8. The prese...
|
|
WO/2022/263792A1 |
The present invention relates to compositions for use in treating or preventing ischaemia reperfusion injury. In particular, the present invention relates to a composition comprising a salt of formula (I): for use in treating or preventi...
|
|
WO/2022/265984A1 |
The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising an NEP inhibitor or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for ...
|
|
WO/2022/264456A1 |
This substance, which specifically binds to the PEX domain (hemopexin domain) of MT1-MMP (MMP-14) and inhibits a MT1-MMP-mediated survival signal to active hepatic stellate cells (aHSCs), can reduce or kill the active hepatic stellate ce...
|
|
WO/2022/264184A1 |
Provided is a pharmaceutical solid-in-oil nano-dispersion composition that may include ascorbic acid or a astable derivative thereof, a surfactant coating the ascorbic acid or its derivative and an oil vehicle, wherein the ascorbic acid ...
|
|
WO/2022/264966A1 |
The purpose of the present invention is to provide medical therapy for treating and/or preventing Rett syndrome (RTT), autism spectrum disorders, or schizophrenia, for which radical treatments have not yet been discovered. The present ...
|
|
WO/2022/265950A1 |
Provided herein are combinations comprising: (i) one or more EGFR inhibitors; and (ii) one or more PERK activators, such as the specific EGFR inhibitors and PERK activators described herein. Also provided herein are methods of treating c...
|
|
WO/2022/165260A9 |
Provided herein are compositions and methods for the treatment of cancers using modified TILs, wherein the modified TILs include one or more immunomodulatory agents (e.g, cytokines) associated with their cell surface. The immunomodulator...
|
|
WO/2022/263476A1 |
The present invention relates to combinations of local anesthetics for improved pain relief in patients.
|
|
WO/2022/266370A1 |
Provided herein are formulations comprising a therapeutically effective amount of sparsentan and methods of treating idiopathic pulmonary fibrosis (IPF) by the administration of said formulations.
|
|
WO/2022/261846A1 |
The present invention provides an antibody targeting an AXL protein or an antigen binding fragment thereof, and a preparation method therefor and an application thereof. Further provided are an isolated polynucleotide encoding the antibo...
|
